Cable Thomas J. sold $277K of OMER

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

Omeros (OMER) shares fell after the European Medicines Agency's CHMP upheld a negative opinion on one of its drugs. The company will terminate the EU compassionate use program and focus on the U.S. market, potentially licensing EU commercialization rights to a third party. OMER stock is down 6% year-to-date, with bearish retail sentiment on Stocktwits.

Omeros Corp. (OMER) shares fell 12% to $16.53 after the European Medicines Agency's committee reaffirmed its negative opinion on narsoplimab for a specific treatment. The stock traded between $15.89 and $17.94. Omeros plans to provide access in Europe and continues U.S. commercialization of YARTEMLEA, approved by the FDA in 2025.

Omeros Corp (OMER) shares fell 4% after the European Medicines Agency upheld its negative opinion on narsoplimab (YARTEMLEA) for treating TA-TMA, despite FDA approval in the US. The company will end its European compassionate-use program and continues developing new applications for the drug.

Omeros (OMER) received a second rejection from the CHMP for narsoplimab in Europe, despite submitting patient-level data. The stock fell 5.04% in pre-market trading. The company plans to discontinue its compassionate-use program for YARTEMLEA in the U.S. due to commercial demand and is advancing other programs within its MASP-2 franchise.

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.